For research use only
| Cat No. | ABC-SC2036 |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | B-Lymphocyte |
| Disease | Facioscapulohumeral Muscular Dystrophy 1 |
| Storage | Liquid Nitrogen |
Cell Type: iPSC; Disease: Facioscapulohumeral Muscular Dystrophy 1; FSHD1.
HighQC™ Human Induced Pluripotent Stem Cells (iPSCs) From B Lymphocytes – Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) are generated from human peripheral blood–derived B lymphocytes obtained from an affected individual. Facioscapulohumeral Muscular Dystrophy Type 1 is a heritable neuromuscular disorder. These cells display tight colony boundaries, high nuclear-to-cytoplasmic ratios, and clonal growth patterns. Reprogramming was performed using a non-integrating approach, which transiently expresses key human transcription factors to initiate the reprogramming process. These iPSCs exhibit pluripotency, with the ability to differentiate into types of all three germ layers under defined conditions, and express the pluripotency marker SSEA-4. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HighQC™ Human IPSC From B-Lymphocyte (Facioscapulohumeral Muscular Dystrophy 1), HighQC™ hiPSC FSHD1, hiPSC-FSHD1, HighQC™ Human Induced Pluripotent Stem Cells From B-Lymphocyte-Facioscapulohumeral Muscular Dystrophy Type 1 |
| Species | Human |
| Cat.No | ABC-SC2036 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | B-Lymphocyte |
| Disease | Facioscapulohumeral Muscular Dystrophy 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSCs derived from B lymphocytes of individuals with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), also known as FSHD1 iPSCs, can be directed to differentiate into skeletal muscle lineage cells, including myogenic progenitors and mature myotubes, enabling investigation of muscle development, degeneration, and regeneration associated with FSHD1. These cells are also valuable for in vitro disease modeling, as they retain patient-specific genetic and epigenetic features, supporting studies of pathogenic mechanisms, gene function, and dysregulated signaling pathways underlying FSHD1.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).